BRPI0414816A - queleritrina, análogos dessa e seu uso no tratamento de distúrbio bipolar e outros distúrbios cognitivos - Google Patents
queleritrina, análogos dessa e seu uso no tratamento de distúrbio bipolar e outros distúrbios cognitivosInfo
- Publication number
- BRPI0414816A BRPI0414816A BRPI0414816-9A BRPI0414816A BRPI0414816A BR PI0414816 A BRPI0414816 A BR PI0414816A BR PI0414816 A BRPI0414816 A BR PI0414816A BR PI0414816 A BRPI0414816 A BR PI0414816A
- Authority
- BR
- Brazil
- Prior art keywords
- alkyl
- chelerythrin
- treatment
- bipolar disorder
- cognitive disorders
- Prior art date
Links
- 208000020925 Bipolar disease Diseases 0.000 title abstract 3
- RATMHCJTVBHJSU-UHFFFAOYSA-N Dihydrochelerythrine Natural products C1=C2OCOC2=CC2=C(N(C)C(O)C=3C4=CC=C(C=3OC)OC)C4=CC=C21 RATMHCJTVBHJSU-UHFFFAOYSA-N 0.000 title abstract 3
- 208000010877 cognitive disease Diseases 0.000 title abstract 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 4
- 150000003839 salts Chemical class 0.000 abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 239000000654 additive Substances 0.000 abstract 1
- 230000000996 additive effect Effects 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000003277 amino group Chemical group 0.000 abstract 1
- 150000001450 anions Chemical class 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000001054 cortical effect Effects 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 230000002360 prefrontal effect Effects 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
"QUELERITRINA, ANáLOGOS DESSA E SEU USO NO TRATAMENTO DE DISTúRBIO BIPOLAR E OUTROS DISTúRBIOS COGNITIVOS". A presente invenção se relaciona ao uso de queleritrina e análogos de queleritrina em composições farmacêuticas para o tratamento de distúrbio cognitivos corticais pré-frontais, que incluem distúrbio bipolar, entre outros. Composições farmacêuticas de acordo com a presente invenção compreendem uma quantidade eficaz de de um composto ou um estereoisómero, sal, solvato ou polimorfo farmaceuticamente aceitável desse de acordo com a estrutura: fórmula (I) ou fórmula (II) na qual: R¬ 1¬ e R¬ 2¬ são independentemente selecionados de H, C~ 1~-C~ 3~ alquil, F, Cl, Br, I, OH, O (C~ 1~-C~ 6~ alquil) , O-C (=O) - (C~ 1~-C~ 6~) alquil ou C(=O)-O- (C~ 1~-C~ 6~) alquil; R¬ 3¬ é H ou um grupo C~ 1~-C~ 6~ alquil; R¬ 4¬, R¬ 5¬, R¬ 6¬, R¬ 7¬ e R¬ 8¬ são independentemente selecionados de H, C~ 1~-C~ 6~ alquil, F, Cl, Br, I, OH, -(CH~ 2~)~ n~O(C~ 1~-C~ 6~ alquil), -(CH~ 2~)~ n~O-C(=O)-(C~ 1~-C~ 6~) alquil ou -(CH~ 2~)~ n~C(=O)-O-(C~ 1~-C~ 6~) alquil; R¬ 9¬ e R¬ 10¬ são independentemente H, C~ 1~-C~ 6~ alquil ou juntos formam um grupo -(CH~ 2~)~ m~- para produzir um anel de 5-7 membros; n é de 0 a 5; m é de 1 a 3; e A- é um ânion farmaceuticamente aceitável de um sal farmacêutico, que forma um sal com o grupo de amina quaternizada, opcionalmente em combinação com um transportador, aditivo ou excipiente farmaceuticamente aceitável.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/672,626 US20050070565A1 (en) | 2003-09-26 | 2003-09-26 | Chelerythrine, analogs thereof and their use in the treatment of bipolar disorder and other cognitive disorders |
| PCT/US2004/031567 WO2005030143A2 (en) | 2003-09-26 | 2004-09-27 | Chelerythrine, analogs thereof and their use in the treatment of bipolar disorder and other cognitive disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0414816A true BRPI0414816A (pt) | 2006-11-14 |
Family
ID=34376422
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0414816-9A BRPI0414816A (pt) | 2003-09-26 | 2004-09-27 | queleritrina, análogos dessa e seu uso no tratamento de distúrbio bipolar e outros distúrbios cognitivos |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20050070565A1 (pt) |
| EP (1) | EP1662875A4 (pt) |
| JP (1) | JP2007506784A (pt) |
| CN (1) | CN1859846A (pt) |
| AU (1) | AU2004275852A1 (pt) |
| BR (1) | BRPI0414816A (pt) |
| CA (1) | CA2540151A1 (pt) |
| IL (1) | IL174303A0 (pt) |
| MX (1) | MXPA06003423A (pt) |
| NO (1) | NO20061357L (pt) |
| WO (1) | WO2005030143A2 (pt) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080145351A1 (en) * | 2000-04-20 | 2008-06-19 | The Research Foundation Of State University Of New York | Memory influencing protein |
| US7928070B2 (en) | 2000-04-20 | 2011-04-19 | The Research Foundation Of State University Of Ny | Memory enhancing protein |
| EP1993612A4 (en) * | 2006-01-31 | 2010-05-05 | Univ Yale | COMPOSITIONS AND METHODS FOR TREATING COGNITIVE INTERFERENCE |
| US8362028B2 (en) * | 2006-07-31 | 2013-01-29 | Yale University | Pseudobase benzo[c]phenanthridines with improved efficacy, stability and safety |
| WO2008048194A1 (en) * | 2006-10-20 | 2008-04-24 | Yesilogluj Aysegul Yildiz | Use of the protein kinase c inhibitor tamoxifen for the treatment of bipolar disorder |
| CN101209043B (zh) * | 2006-12-27 | 2011-08-10 | 长沙世唯科技有限公司 | 血根碱或白屈菜红碱在血吸虫病防治上的应用 |
| WO2008118403A2 (en) * | 2007-03-22 | 2008-10-02 | Yale University | Method of using a pkc inhibitor to reverse prefrontal cortical declines |
| US20120201908A1 (en) * | 2009-08-19 | 2012-08-09 | Lunera Equities, Lllp | Method of treating bipolar disorder or depression using an antiestrogen |
| US20170189391A1 (en) * | 2015-12-31 | 2017-07-06 | Macau University of Science ang Technology | Protein kinase C inhibitor for treating triple-negative breast cancer |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683133A (en) * | 1985-08-20 | 1987-07-28 | Vipont Laboratories, Inc. | Method for treating periodontal disease |
| US5747502A (en) * | 1989-12-13 | 1998-05-05 | Nippon Kayaku Kabushiki Kaisha | Process for preparing benzo c!phenanthridinium derivatives, novel compounds prepared by said process, and antitumor agents |
| JP2784104B2 (ja) * | 1991-08-06 | 1998-08-06 | 三菱電機株式会社 | タイミングシミュレーションシステム |
| US5922571A (en) * | 1997-03-06 | 1999-07-13 | Incyte Pharmaceuticals, Inc. | Polynucleotides encoding a protein kinase C homolog |
| US6717030B2 (en) * | 1998-07-06 | 2004-04-06 | The Regents Of The University Of California | Protein kinase C epsilon as modulator of anxiety, alcohol consumption and self-administration of drugs of abuse |
| AUPQ801700A0 (en) * | 2000-06-07 | 2000-06-29 | Peplin Research Pty Ltd | Enzyme and viral activation |
| US6664266B2 (en) * | 2002-03-14 | 2003-12-16 | Children's Medical Center Corporation | Axon regeneration with PKC inhibitiors |
-
2003
- 2003-09-26 US US10/672,626 patent/US20050070565A1/en not_active Abandoned
-
2004
- 2004-09-27 CN CNA2004800280172A patent/CN1859846A/zh active Pending
- 2004-09-27 MX MXPA06003423A patent/MXPA06003423A/es unknown
- 2004-09-27 BR BRPI0414816-9A patent/BRPI0414816A/pt not_active IP Right Cessation
- 2004-09-27 EP EP04785084A patent/EP1662875A4/en not_active Withdrawn
- 2004-09-27 AU AU2004275852A patent/AU2004275852A1/en not_active Abandoned
- 2004-09-27 CA CA002540151A patent/CA2540151A1/en not_active Abandoned
- 2004-09-27 WO PCT/US2004/031567 patent/WO2005030143A2/en not_active Ceased
- 2004-09-27 JP JP2006528278A patent/JP2007506784A/ja not_active Withdrawn
-
2006
- 2006-03-13 IL IL174303A patent/IL174303A0/en unknown
- 2006-03-24 NO NO20061357A patent/NO20061357L/no not_active Application Discontinuation
-
2009
- 2009-08-25 US US12/546,737 patent/US20100222376A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2004275852A1 (en) | 2005-04-07 |
| NO20061357L (no) | 2006-06-16 |
| EP1662875A4 (en) | 2009-04-15 |
| WO2005030143A2 (en) | 2005-04-07 |
| CA2540151A1 (en) | 2005-04-07 |
| US20050070565A1 (en) | 2005-03-31 |
| IL174303A0 (en) | 2006-08-01 |
| US20100222376A1 (en) | 2010-09-02 |
| WO2005030143A3 (en) | 2005-09-15 |
| CN1859846A (zh) | 2006-11-08 |
| EP1662875A2 (en) | 2006-06-07 |
| MXPA06003423A (es) | 2006-06-27 |
| JP2007506784A (ja) | 2007-03-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0014116A (pt) | Uso de um composto, composto, métodos para preparação de um composto, e para inibir aurora 2 quinase em um animal de sangue quente, e, composição farmacêutica | |
| BRPI0612926B8 (pt) | compostos fluorados de 4-(2-amino-1-hidroxietila)fenol como agonistas de receptores b2 adrenérgicos, composição farmacêutica, combinação e uso de um composto | |
| AP2001002307A0 (en) | B3 adrenergic receptor agonists and uses thereof. | |
| UY28374A1 (es) | Agentes terapéuticos | |
| BRPI0518068A (pt) | composto ou um éster ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica, inibidor seletivo de aurora a, agente anti-tumor, e, preparação combinada | |
| WO2008012635A3 (en) | Amine derivatives useful as anticancer agents | |
| BR0112475A (pt) | N-óxidos como pró-drogas antagonistas de receptor de nk1 de derivados 4-fenil-piridina | |
| BR0317435A (pt) | Derivados de pirimidina para o tratamento do crescimento celular anormal | |
| CO6270330A2 (es) | 2-fluoro-2`-desoxitetrahidrouridinas como inhibidores de citidina desaminasa | |
| BR0308261A (pt) | Métodos extrativos para puruficação de sucralose | |
| SE0104334D0 (sv) | Therapeutic agents | |
| ECSP066730A (es) | Compuestos y procedimientos para uso | |
| IL189156A (en) | A bite-containing (theo-hydrazide-rich) preparation, a flake cation and a thickening additive, a method for making this lipophilate and the leophilizate | |
| BR0308495A (pt) | Composto, formulação farmacêutica, métodos para ativar receptores de 5-ht1f, para inibir o extravasamento de proteìna neuronal, para tratar ou prevenir enxaqueca em um mamìfero e para preparar um composto, uso de um composto, e, processo para preparar um composto | |
| WO2008002596A3 (en) | Adenosine a2a receptor antagonists | |
| ECSP034628A (es) | Formas de sal de amida de acido 3-(4-bromo-2,6-difluorobenciloxi)-5-[3-(4-oirrolidin-1-ilbutil) ureido] isotiazol-4-carboxilico y metodo de produccion | |
| AR024060A1 (es) | Nuevos compuestos farmaceuticamente activos | |
| BRPI0518360A2 (pt) | composto e sais farmaceuticamente aceitÁveis do mesmo, composiÇço farmacÊutica, uso de um composto, e, processo para preparar um composto ou um sal farmaceuticamente aceitÁvel do mesmo | |
| BRPI0414816A (pt) | queleritrina, análogos dessa e seu uso no tratamento de distúrbio bipolar e outros distúrbios cognitivos | |
| BR0112337A (pt) | Derivados de fosfolipìdeos de ácido valpróico e suas misturas | |
| BR9814055A (pt) | Composto, composição farmacêutica, processo para o tratamento de uma doença alérgica, uso do composto, e, processos para preparar e para produzir um composto | |
| AR049385A1 (es) | Sulfoniletil fosforodiamidatos | |
| BRPI0509512A (pt) | método de tratar esquizofrenia e/ou anormalidades glicorregulatórias | |
| BRPI0518615A2 (pt) | derivados de malonamida | |
| AR033300A1 (es) | Compuestos de cefem |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012. |